Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY-NCSakarya Üniversitesi Fen Bilimleri Enstitüsü Dergisi

Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models

  • Ahmet Ali Berber1
  • Sinem Öztürk1
  1. 1CANAKKALE ONSEKIZ MART UNIVERSITY
Read full textPDFDOICite

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) offer reduced gastrointestinal toxicity compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), yet their safety remains controversial as evidenced by several market withdrawals due to severe cardiovascular and hepatic risks. This study systematically evaluated 16 human and veterinary coxib compounds for mutagenicity, carcinogenicity, micronucleus activity, and hepatotoxicity through a multi-platform in silico approach using VEGA-QSAR, ToxTree, and T.E.S.T. software. The results indicated that while widely used agents like Celecoxib and Etoricoxib exhibit safer profiles, compounds such as Lumiracoxib and NS-398 possess significant carcinogenic and mutagenic potential. Notably, high-reliability hepatotoxicity alerts were identified for several veterinary-grade coxibs, raising significant public health concerns regarding drug residues in the equine-derived food chain and potential human exposure. Discrepancies observed between different predictive models highlight the limitations of individual algorithms and underscore the necessity of a consensus approach to improve the robustness of risk evaluations. This study provides an essential foundational framework for the safety assessment of coxib derivatives and emphasizes the critical importance of validating in silico alerts with targeted in vivo research, particularly in the context of food safety and drug residue management.

Related

  1. Integrated Chemical Profiling and Toxicological Assessment of Total Polyphenols from Cydonia oblonga Mill. Reveals Potential Safety Concerns Under High-Dose Exposure.
    Alifeiye Aikebaier, Alhar Baishan, Kayisaier Abudurousuli +7
    Foods (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
    Alessandro Russo, Christian Rolfo, Mariacarmela Santarpia
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy
    M. Fuentes-Baile, J. A. Encinar, S. Araujo-Abad +5
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. Engineering T cell-selective chemokine inhibitors through network-level directed evolution
    Megan Payne, Fernando Durães, Charlie J. Clark +7
    Communications BiologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  5. The safety of selective COX-2 inhibitors in tonsillectomy patients: a systematic review
    Sophie Dunmall, Lucylynn Lizarondo, Romy Jia +1
    The Journal of Laryngology and OtologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMC

Cite

BibTeXRIS
BibTeX
@article{berber2026comparative,
  title = {{Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models}},
  author = {Ahmet Ali Berber and Sinem Öztürk},
  journal = {Sakarya Üniversitesi Fen Bilimleri Enstitüsü Dergisi},
  year = {2026},
  month = oct,
  doi = {10.16984/saufenbilder.1867893},
  url = {https://doi.org/10.16984/saufenbilder.1867893},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Comparative in Silico Toxicological Assessment of 16 Selective COX-2 Inhibitors (Coxibs) Using Multi-Platform Predictive Models
AU  - Ahmet Ali Berber
AU  - Sinem Öztürk
PY  - 2026
DA  - 2026/10/01
JO  - Sakarya Üniversitesi Fen Bilimleri Enstitüsü Dergisi
DO  - 10.16984/saufenbilder.1867893
UR  - https://doi.org/10.16984/saufenbilder.1867893
AB  - Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) offer reduced gastrointestinal toxicity compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), yet their safety remains controversial as evidenced by several market withdrawals due to severe cardiovascular and hepatic risks. This study systematically evaluated 16 human and veterinary coxib compounds for mutagenicity, carcinogenicity, micronucleus activity, and hepatotoxicity through a multi-platform in silico approach using VEGA-QSAR, ToxTree, and T.E.S.T. software. The results indicated that while widely used agents like Celecoxib and Etoricoxib exhibit safer profiles, compounds such as Lumiracoxib and NS-398 possess significant carcinogenic and mutagenic potential. Notably, high-reliability hepatotoxicity alerts were identified for several veterinary-grade coxibs, raising significant public health concerns regarding drug residues in the equine-derived food chain and potential human exposure. Discrepancies observed between different predictive models highlight the limitations of individual algorithms and underscore the necessity of a consensus approach to improve the robustness of risk evaluations. This study provides an essential foundational framework for the safety assessment of coxib derivatives and emphasizes the critical importance of validating in silico alerts with targeted in vivo research, particularly in the context of food safety and drug residue management.
SN  - 2147-835X
SN  - 1301-4048
ER  -